

Clinical Care Pathway

Clinical Care Pathway for the Risk Stratification and Management of Patients with Nonalcoholic Fatty Liver Disease-Gastroenterology 2021:1-13. <https://doi.org/10.1053/j.gastro.2021.07.049>

Figure 3: Management of NAFLD/NASH

	LOW RISK FIB-4 < 1.3 or LSM < 8 kPa or liver biopsy F0-F1	INDETERMINATE RISK FIB-4 1.3 - 2.67 and/or LSM 8 - 12 kPa and liver biopsy not available	HIGH RISK¹ FIB-4 > 2.67 or LSM > 12 kPa or liver biopsy <u>F2-F4</u>
	Management by PCP, dietician, endocrinologist, cardiologist, others	Management by hepatologist with multidisciplinary team (PCP, dietician, endocrinologist, cardiologist, others)	
Lifestyle intervention ²	Yes	Yes	Yes
Weight loss recommended if overweight or obese ³	Yes May benefit from structured weight loss programs, anti-obesity medications, bariatric surgery	Yes Greater need for structured weight loss programs, anti-obesity medications, bariatric surgery	Yes Strong need for structured weight loss programs, anti-obesity medications, bariatric surgery
Pharmacotherapy for NASH	Not recommended	Yes ^{4, 5}	Yes ^{4, 5}
CVD risk reduction ⁶	Yes	Yes	Yes
Diabetes care	Standard of care	Prefer medications with efficacy in NASH (pioglitazone, <u>GLP-1 RA</u>)	Prefer medications with efficacy in NASH (pioglitazone, GLP-1 RA)